Literature DB >> 11484819

Mutational analysis of INI1 in sporadic human brain tumors.

M Weber1, F Stockhammer, U Schmitz, A von Deimling.   

Abstract

The INI1/SMARCB1/hSNF5 gene on chromosome 22 is frequently mutated in rhabdoid tumors. An association of INI1 mutations with allelic losses on chromosome 22 supports a classical tumor suppressor mechanism. Several brain tumor entities including astrocytomas, glioblastomas and ependymomas are characterized by allelic losses on chromosome 22. In the present study we examined a series of 200 brain tumors by Single-strand conformation polymorphism analysis and direct sequencing for point mutations in INI1. In addition, all tumors were analyzed for homozygous deletions spanning both exons 3 and 8 of INI1. No mutations or homozygous deletions were detected in astrocytomas, glioblastomas, oligodendroglial tumors, neurinomas or medulloblastomas. However, a point mutation could be identified in the single case of plexus carcinoma. Our data suggest that INI1 mutations are involved in the pathogenesis of plexus carcinoma; however, INI1 alterations are not a frequent event in the majority of brain tumor entities.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11484819     DOI: 10.1007/s004010000316

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  10 in total

1.  Atypical molecular background of glioblastoma and meningioma developed in a patient with Li-Fraumeni syndrome.

Authors:  Piotr Rieske; Magdalena Zakrzewska; Wojciech Biernat; Jacek Bartkowiak; Arthur Zimmermann; Paweł Piotr Liberski
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

2.  SNF5 as a prognostic factor in skull base chordoma.

Authors:  Mingxuan Li; Yixuan Zhai; Jiwei Bai; Shuai Wang; Hua Gao; Chuzhong Li; Songbai Gui; Jiang Du; Yazhuo Zhang
Journal:  J Neurooncol       Date:  2017-12-08       Impact factor: 4.130

3.  Cyclin D1 is overexpressed in atypical teratoid/rhabdoid tumor with hSNF5/INI1 gene inactivation.

Authors:  Hironori Fujisawa; Koichi Misaki; Yasushi Takabatake; Mitsuhiro Hasegawa; Junkoh Yamashita
Journal:  J Neurooncol       Date:  2005-06       Impact factor: 4.130

4.  Chromosomal imbalances in choroid plexus tumors.

Authors:  Christian H Rickert; Otmar D Wiestler; Werner Paulus
Journal:  Am J Pathol       Date:  2002-03       Impact factor: 4.307

Review 5.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

6.  Molecular analysis of the rhabdoid predisposition syndrome in a child: a novel germline hSNF5/INI1 mutation and absence of c-myc amplification.

Authors:  Hironori Fujisawa; Yasushi Takabatake; Toshio Fukusato; Osamu Tachibana; Yoshitake Tsuchiya; Junkoh Yamashita
Journal:  J Neurooncol       Date:  2003-07       Impact factor: 4.130

7.  Pediatric embryonal tumor with epithelial immunophenotype showing absence of hSNF5/INI1 expression.

Authors:  Keiichi Sakai; Hiroaki Shigeta; Yoshifumi Ogiso; Kazuhiro Hongo; Shigeaki Kobayashi; Takanori Hirose
Journal:  Childs Nerv Syst       Date:  2004-05-25       Impact factor: 1.475

8.  SMARCB1 Acts as a Quiescent Gatekeeper for Cell Cycle and Immune Response in Human Cells.

Authors:  Sung Kyung Choi; Myoung Jun Kim; Jueng Soo You
Journal:  Int J Mol Sci       Date:  2020-06-01       Impact factor: 5.923

9.  Mutations in SMARCB1 and in other Coffin-Siris syndrome genes lead to various brain midline defects.

Authors:  Alina Filatova; Linda K Rey; Marion B Lechler; Jörg Schaper; Maja Hempel; Renata Posmyk; Krzysztof Szczaluba; Gijs W E Santen; Dagmar Wieczorek; Ulrike A Nuber
Journal:  Nat Commun       Date:  2019-07-04       Impact factor: 14.919

10.  Long-term survival and transmission of INI1-mutation via nonpenetrant males in a family with rhabdoid tumour predisposition syndrome.

Authors:  A C J Ammerlaan; A Ararou; M P W A Houben; F Baas; C C Tijssen; J L J M Teepen; P Wesseling; T J M Hulsebos
Journal:  Br J Cancer       Date:  2007-12-18       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.